Amlocard - General Information:A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of angina pectoris and hypertension. [PubChem]
Other Brand Names containing Amlodipine
Amlocard - Pharmacology:
Amlocard is a calcium channel blocking agent. It inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase I activity with consecutive pH increase which may be involved in intracelluar calcium influx through calcium channels.
Amlocard for patients
Amlodipine besylate is ued to treat high blood pressure and a heart condition called angina.
It is referred to as a calcium-channel blocker. The most common side effects include headache
and swelling (edema). If you experience difficulty breathing, contact your doctor immediately.
Rarely, in patients with severe disease, more frequent and more sever chest pain has been reported.
If this occurs, contact your doctor immediately. There have been no significant drug interactions
reported to date. Dizziness and lightheadedness can result when the mediation is first started.
If this persists longer than one week, contact your physician. Your blood pressure should be
checked regularly to assure adequate control
In vitro data indicate that NORVASC has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.
Effect of other agents on NORVASC.
CIMETIDINE: Co-administration of NORVASC with cimetidine did not alter the pharmacokinetics of NORVASC.
GRAPEFRUIT JUICE: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.
MAALOX (antacid): Co-administration of the antacid Maalox with a single dose of NORVASC had no significant effect on the pharmacokinetics of NORVASC.
SILDENAFIL: A single 100 mg dose of sildenafil (ViagraÒ) in subjects with essential hypertension had no effect on the pharmacokinetic parameters of NORVASC. When NORVASC and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.
Effect of NORVASC on other agents.
ATORVASTATIN: Co-administration of multiple 10 mg doses of NORVASC with 80 mg of atorvastatin resulted in no significant change in the steady state pharmacokinetic parameters of atorvastatin.
DIGOXIN: Co-administration of NORVASC with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.
ETHANOL (alcohol): Single and multiple 10 mg doses of NORVASC had no significant effect on the pharmacokinetics of ethanol.
WARFARIN: Co-administration of NORVASC with warfarin did not change the warfarin prothrombin response time.
In clinical trials, NORVASC has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.
Drug/Laboratory Test Interactions: None known.
NORVASC is contraindicated in patients with known sensitivity to amlodipine.
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..